Tag: Diabetes Therapeutics Market Analysis

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Diabetes Therapeutics Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?

The diabetes therapeutics market has experienced substantial expansion in recent years. It is anticipated to increase from $170.06 billion in 2025 to $188.19 billion in 2026, reflecting a compound annual growth rate (CAGR) of 10.7%. Historically, this growth was influenced by factors such as the limited availability of advanced therapeutics, a reliance on traditional oral anti-diabetic drugs, low awareness of preventive care, constrained distribution channels, and the growing burden of type 2 diabetes.

The diabetes therapeutics market is projected to experience substantial expansion in the coming years. By 2030, its value is anticipated to reach $278.96 billion, exhibiting a compound annual growth rate (CAGR) of 10.3%. This forecasted increase is primarily driven by factors such as the creation of new insulin analogs, the proliferation of combination treatments, the uptake of digital tools for diabetes management, improvements in healthcare infrastructure dedicated to diabetes care, and the incorporation of telemedicine alongside remote monitoring services. Key trends observed during this period encompass the escalating global incidence of diabetes, the heightened utilization of GLP-1 receptor agonists and SGLT-2 inhibitors, the broadening reach of online and physical pharmacies, a greater emphasis on individualized diabetes management approaches, and improved understanding of preventative measures and timely detection.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=73676434&type=smp&name=Diabetes%20Therapeutics%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Diabetes Therapeutics Market Industry Drivers: What’s Behind The Revenue Growth?

The rising incidence of obesity is anticipated to drive expansion in the diabetes therapeutics market moving ahead. Obesity, defined as an unhealthy excess accumulation of body fat, poses a significant health risk and stands as a primary contributor to type 2 diabetes. This growing occurrence of obesity stems from a higher intake of calorie-dense diets, as more individuals consume processed and fast foods rich in sugar and fat while undertaking reduced physical activity, resulting in substantial weight gain. Diabetes treatments aid in managing obesity by enhancing blood sugar regulation and facilitating weight reduction via medications like GLP-1 receptor agonists, which work to decrease appetite and prolong digestion, thereby improving the overall metabolic well-being of obese individuals. For example, in May 2024, a report released by the Office for Health Improvement and Disparities, a UK-based government department, indicated that from 2022 to 2023, approximately 64% of adults aged 18 and over were categorized as overweight or obese, marking an increase from the preceding year’s figure of 63.8%. Consequently, the expanding prevalence of obesity is fueling the development of the diabetes therapeutics market.

Diabetes Therapeutics Market Segment Analysis: What Are The Core Market Categories?

The diabetes therapeutics market covered in this report is segmented –

1) By Drug: Oral Anti-Diabetic Drugs, Insulin, Non-Insulin Injectable Drug, Combination Drug

2) By Type: Diabetes 1, Diabetes 2

3) By Route Of Administration: Oral, Subcutaneous, Intravenous

4) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies

5) By Application: Preventive, Treatment Or Care

Subsegments:

1) By Oral Anti-Diabetic Drugs: Biguanides, Sulfonylureas, DPP-4 Inhibitors, SGLT-2 Inhibitors, Thiazolidinediones, Meglitinides, Alpha-Glucosidase Inhibitors

2) By Insulin: Rapid-Acting Insulin, Short-Acting Insulin, Intermediate-Acting Insulin, Long-Acting Insulin, Premixed Insulin

3) By Non-Insulin Injectable Drug: GLP-1 Receptor Agonists, Amylin Analogs

4) By Combination Drug: Oral Combination Therapies, Oral and Injectable Combination Therapies

#Diabetes Therapeutics Market Growth Trends: What’s Shaping The Future Outlook?

Leading firms within the diabetes therapeutics sector are prioritizing the creation of novel solutions, including cognitive behavioral therapy (CBT), with the aim of advancing individualized diabetes care and optimizing glycemic control for individuals living with type 2 diabetes. Cognitive behavioral therapy (CBT) is defined as a systematic, evidence-supported psychological intervention designed to assist people in recognizing and modifying detrimental thought processes and actions. As an illustration, in October 2023, Better Therapeutics Inc., a digital therapeutics company based in the US, introduced AspyreRx, a digital application for diabetes therapy. AspyreRx, having secured FDA authorization for addressing type 2 diabetes, delivers customized cognitive behavioral therapy (CBT) to patients aged 18 and older, thereby facilitating behavioral modifications conducive to enhanced diabetes management. Previously identified as BT-001, AspyreRx exhibited statistically and clinically meaningful, sustained decreases in A1c when contrasted with conventional care, in addition to benefits in blood pressure, weight, mood, and overall quality of life during a randomized controlled trial.

Diabetes Therapeutics Market Top Companies Driving Competitive Growth

Major companies operating in the diabetes therapeutics market are Pfizer Inc., Merck & Co Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Biocon Biologics Limited, MannKind Corporation, Lexicon Pharmaceuticals Inc., Adocia S.A., Oramed Pharmaceuticals Inc.

View The Full Diabetes Therapeutics Market Report:

https://thebusinessresearchcompany.com/report/diabetes-therapeutics-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Diabetes Therapeutics Market Geographic Analysis: Where Is Demand Accelerating Fastest?

North America was the largest region in the diabetes therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetes therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Diabetes Therapeutics Market Expected To Reach $278.96 Billion By 2030 At 10.3% CAGR

The diabetes therapeutics market has experienced significant expansion in recent times, with projections indicating an increase from $170.06 billion in 2025 to $188.19 billion in 2026, reflecting a compound annual growth rate (CAGR) of 10.7%. This historical growth has been driven by several factors, including the restricted accessibility of advanced therapeutic options, a heavy dependence on conventional oral anti-diabetic medications, insufficient awareness regarding preventive healthcare measures, limited distribution networks, and the escalating prevalence of type 2 diabetes.

The diabetes therapeutics market is anticipated to experience swift expansion over the coming years, reaching an estimated value of $278.96 billion by 2030, with a compound annual growth rate (CAGR) of 10.3%. This projected growth during the forecast period is driven by factors such as the creation of novel insulin analogs, the broadening of combination therapies, the uptake of digital tools for diabetes management, improvements in healthcare infrastructure dedicated to diabetes care, and the incorporation of telemedicine alongside remote monitoring capabilities. Key trends shaping this period include the global surge in diabetes prevalence, the growing utilization of GLP-1 receptor agonists and SGLT-2 inhibitors, the expansion of online and retail pharmacy channels, an intensified emphasis on customized diabetes management, and heightened awareness surrounding preventive care and early detection.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25749&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Diabetes Therapeutics Market Opportunity Drivers: What Is Creating New Revenue Potential?

The ongoing rise in obesity rates is anticipated to fuel expansion in the diabetes therapeutics market in the coming years. Obesity, characterized by an abnormal accumulation of body fat that poses health risks, serves as a significant contributor to type 2 diabetes. This trend is largely driven by a heightened intake of calorie-dense diets, as more individuals consume processed and fast foods rich in sugar and fat, combined with reduced physical activity, which results in excessive weight gain. Diabetes therapeutics address obesity by enhancing blood sugar regulation and facilitating weight loss through agents like GLP-1 receptor agonists, which curb appetite and slow digestive processes, thereby improving overall metabolic function in those who are obese. For example, a May 2024 report from the Office for Health Improvement and Disparities, a UK governmental body, indicated that between 2022 and 2023, roughly 64% of adults aged 18 and older were categorized as overweight or obese, marking an increase from 63.8% in the prior year. Consequently, the growing prevalence of obesity is propelling the diabetes therapeutics market forward.

Diabetes Therapeutics Market Segments: Where Are The Largest Growth Opportunities?

The diabetes therapeutics market covered in this report is segmented –

1) By Drug: Oral Anti-Diabetic Drugs, Insulin, Non-Insulin Injectable Drug, Combination Drug

2) By Type: Diabetes 1, Diabetes 2

3) By Route Of Administration: Oral, Subcutaneous, Intravenous

4) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies

5) By Application: Preventive, Treatment Or Care

Subsegments:

1) By Oral Anti-Diabetic Drugs: Biguanides, Sulfonylureas, DPP-4 Inhibitors, SGLT-2 Inhibitors, Thiazolidinediones, Meglitinides, Alpha-Glucosidase Inhibitors

2) By Insulin: Rapid-Acting Insulin, Short-Acting Insulin, Intermediate-Acting Insulin, Long-Acting Insulin, Premixed Insulin

3) By Non-Insulin Injectable Drug: GLP-1 Receptor Agonists, Amylin Analogs

4) By Combination Drug: Oral Combination Therapies, Oral and Injectable Combination Therapies

Diabetes Therapeutics Market Innovation Trends Driving Future Development

Major players within the diabetes therapeutics sector are concentrating on the development of advanced approaches like cognitive behavioral therapy (CBT) to improve customized diabetes care and achieve better blood sugar control in individuals with type 2 diabetes. This evidence-based psychological treatment, known as cognitive behavioral therapy, is organized to assist patients in recognizing and adjusting detrimental thinking patterns and behaviors. An example of this progress is seen in October 2023, when Better Therapeutics Inc., a digital therapeutic company based in the United States, introduced AspyreRx, a specialized digital tool for diabetes management. This app, which gained FDA clearance for treating type 2 diabetes, delivers tailored cognitive behavioral therapy to individuals 18 years and older, promoting lifestyle changes that enhance the control of their condition. Previously designated as BT-001, AspyreRx achieved meaningful and clinically confirmed reductions in A1c levels relative to usual care, along with enhancements in blood pressure, weight, emotional state, and overall quality of life, as demonstrated through a randomized controlled trial.

Diabetes Therapeutics Market Major Participants And Competitive Dynamics

Major companies operating in the diabetes therapeutics market are Pfizer Inc., Merck & Co Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Biocon Biologics Limited, MannKind Corporation, Lexicon Pharmaceuticals Inc., Adocia S.A., Oramed Pharmaceuticals Inc.

Access The Complete Diabetes Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/diabetes-therapeutics-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Diabetes Therapeutics Market Leading Geography: Which Region Generates The Most Revenue?

North America was the largest region in the diabetes therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetes therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Diabetes Therapeutics Market Expected To Scale Between 2026 And 2030?

The diabetes therapeutics market size has experienced rapid expansion in recent years. It is projected to increase from $170.06 billion in 2025 to $188.19 billion in 2026, at a compound annual growth rate (CAGR) of 10.7%. The market’s historical growth can be attributed to the limited availability of advanced therapeutics, a reliance on traditional oral anti-diabetic drugs, low awareness of preventive care, constrained distribution channels, and the growing burden of type 2 diabetes.

The diabetes therapeutics market size is projected to experience substantial growth in the upcoming years, with an expected increase to $278.96 billion by 2030, achieving a compound annual growth rate (CAGR) of 10.3%. This expansion during the forecast period is primarily driven by the introduction of novel insulin analogs, the broadening availability of combination therapies, the widespread adoption of digital diabetes management solutions, a growing healthcare infrastructure dedicated to diabetes care, and the seamless integration of telemedicine and remote monitoring. Significant trends expected in this period include the escalating global prevalence of diabetes, an increased uptake of GLP-1 receptor agonists and SGLT-2 inhibitors, the expansion of both online and retail pharmacy networks, a concentrated focus on personalized diabetes management, and improved awareness regarding preventive care and early diagnosis.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25749&type=smp

Which Drivers Are Supporting The Diabetes Therapeutics Market Growth?

The growing incidence of obesity is projected to boost the expansion of the diabetes therapeutics market in the future. Obesity, characterized by an unhealthy accumulation of body fat, poses a significant health hazard and stands as a primary risk factor for type 2 diabetes. This rise in obesity can be attributed to increased consumption of high-calorie diets, as more individuals opt for processed and fast foods rich in sugar and fat, alongside reduced physical activity, resulting in substantial weight gain. Diabetes therapeutics aid in managing obesity by enhancing blood sugar regulation and facilitating weight loss through various medications, including GLP-1 receptor agonists. These agonists work by decreasing appetite and slowing down digestion, thereby improving the overall metabolic well-being of obese individuals. For example, a report from May 2024, issued by the UK’s Office for Health Improvement and Disparities, indicated that from 2022 to 2023, around 64% of adults aged 18 and above were classified as either overweight or obese. This figure represents an increase from the 63.8% recorded in the preceding year. Consequently, the expanding prevalence of obesity is a key driver for the growth within the diabetes therapeutics market.

Which Segment Categories Are Included In The Diabetes Therapeutics Market Segment Analysis?

The diabetes therapeutics market covered in this report is segmented –

1) By Drug: Oral Anti-Diabetic Drugs, Insulin, Non-Insulin Injectable Drug, Combination Drug

2) By Type: Diabetes 1, Diabetes 2

3) By Route Of Administration: Oral, Subcutaneous, Intravenous

4) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies

5) By Application: Preventive, Treatment Or Care

Subsegments:

1) By Oral Anti-Diabetic Drugs: Biguanides, Sulfonylureas, DPP-4 Inhibitors, SGLT-2 Inhibitors, Thiazolidinediones, Meglitinides, Alpha-Glucosidase Inhibitors

2) By Insulin: Rapid-Acting Insulin, Short-Acting Insulin, Intermediate-Acting Insulin, Long-Acting Insulin, Premixed Insulin

3) By Non-Insulin Injectable Drug: GLP-1 Receptor Agonists, Amylin Analogs

4) By Combination Drug: Oral Combination Therapies, Oral and Injectable Combination Therapies

Which Trends Are Guiding The Direction Of The Diabetes Therapeutics Market?

Leading companies in the diabetes therapeutics market are concentrating on developing innovative solutions, such as cognitive behavioral therapy (CBT), to improve personalized diabetes management and glycemic control for patients with type 2 diabetes. Cognitive behavioral therapy (CBT) is a structured, evidence-based psychological treatment designed to help individuals identify and alter unhelpful thought patterns and behaviors. For example, in October 2023, Better Therapeutics Inc., a US-based digital therapeutics company, released AspyreRx, a digital therapeutic app for diabetes. AspyreRx, which secured FDA authorization for treating type 2 diabetes, offers personalized cognitive behavioral therapy (CBT) to patients aged 18 and older, supporting behavioral changes that enhance diabetes management. Formerly known as BT-001, AspyreRx showed statistically and clinically significant, enduring reductions in A1c when compared to standard care, alongside improvements in blood pressure, weight, mood, and quality of life in a randomized controlled trial.

Who Are The Active Companies Shaping The Diabetes Therapeutics Market?

Major companies operating in the diabetes therapeutics market are Pfizer Inc., Merck & Co Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Biocon Biologics Limited, MannKind Corporation, Lexicon Pharmaceuticals Inc., Adocia S.A., Oramed Pharmaceuticals Inc.

Get The Full Diabetes Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/diabetes-therapeutics-global-market-report

Where Is The Diabetes Therapeutics Market Most Concentrated Geographically?

North America was the largest region in the diabetes therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetes therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Diabetes Therapeutics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/diabetes-therapeutics-global-market-report

Browse Through More Reports Similar to the Global Diabetes Therapeutics Market 2026, By The Business Research Company

Antidiabetics Market Report 2026

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Non Insulin Therapies For Diabetes Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-insulin-therapies-for-diabetes-global-market-report

Antidiabetics Market Report 2026

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Diabetes Therapeutics Market During 2026–2030?

The diabetes therapeutics market has expanded swiftly in recent years. It is anticipated to increase from $170.06 billion in 2025 to $188.19 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.7%. The expansion observed historically can be linked to the limited access to advanced therapeutic options, a reliance on conventional oral anti-diabetic drugs, inadequate awareness of preventive healthcare, restricted distribution channels, and the increasing burden of type 2 diabetes.

The diabetes therapeutics market size is projected to undergo significant expansion in the upcoming years. It is expected to reach $278.96 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.3%. This anticipated growth can be attributed to several factors including the development of novel insulin analogs, the increasing availability of combination therapies, the widespread adoption of digital diabetes management tools, enhancements in healthcare infrastructure for diabetes care, and the integration of telemedicine and remote monitoring services. Prominent trends observed during this forecast period include the rising global prevalence of diabetes, the increasing uptake of glp-1 receptor agonists and sglt-2 inhibitors, the broadening reach of online and retail pharmacies, an intensified focus on personalized diabetes management, and improved awareness regarding preventive care and early diagnosis.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25749&type=smp

Which Economic Or Industry Drivers Are Impacting The Diabetes Therapeutics Market?

The growing occurrence of obesity is projected to boost the expansion of the diabetes therapeutics market in the future. Obesity, characterized by an unhealthy excess of fat, poses a significant health hazard and stands as a primary risk factor for type 2 diabetes. The heightened incidence of obesity stems from a greater intake of high-calorie foods, as more individuals consume processed and fast foods rich in sugar and fat, coupled with reduced physical activity, resulting in substantial weight gain. Diabetes therapeutics aid in the management of obesity by enhancing blood sugar regulation and assisting with weight loss, utilizing medications like GLP-1 receptor agonists that diminish appetite and decelerate digestion, thereby improving the overall metabolic health of obese individuals. For example, a report released in May 2024 by the Office for Health Improvement and Disparities, a UK-based government department, indicated that from 2022 to 2023, roughly 64% of adults aged 18 and above were categorized as overweight or obese, representing an increase from the 63.8% recorded in the preceding year. Consequently, the rising occurrence of obesity is fueling the growth of the diabetes therapeutics market.

How Are The Various Segments Of The Diabetes Therapeutics Market Categorized?

The diabetes therapeutics market covered in this report is segmented –

1) By Drug: Oral Anti-Diabetic Drugs, Insulin, Non-Insulin Injectable Drug, Combination Drug

2) By Type: Diabetes 1, Diabetes 2

3) By Route Of Administration: Oral, Subcutaneous, Intravenous

4) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies

5) By Application: Preventive, Treatment Or Care

Subsegments:

1) By Oral Anti-Diabetic Drugs: Biguanides, Sulfonylureas, DPP-4 Inhibitors, SGLT-2 Inhibitors, Thiazolidinediones, Meglitinides, Alpha-Glucosidase Inhibitors

2) By Insulin: Rapid-Acting Insulin, Short-Acting Insulin, Intermediate-Acting Insulin, Long-Acting Insulin, Premixed Insulin

3) By Non-Insulin Injectable Drug: GLP-1 Receptor Agonists, Amylin Analogs

4) By Combination Drug: Oral Combination Therapies, Oral and Injectable Combination Therapies

What Trends Are Affecting The Expansion Of The Diabetes Therapeutics Market?

Leading companies within the diabetes therapeutics market are prioritizing the development of innovative approaches, such as cognitive behavioral therapy (CBT), to enhance customized diabetes care and improve glycemic control for individuals with type 2 diabetes. Cognitive behavioral therapy (CBT) is defined as a structured, empirically supported psychological intervention that assists people in recognizing and altering detrimental thought processes and actions. An illustrative example occurred in October 2023, when Better Therapeutics Inc., a digital therapeutics company based in the US, introduced AspyreRx, a digital application designed for diabetes therapy. AspyreRx, which secured FDA authorization for addressing type 2 diabetes, delivers personalized cognitive behavioral therapy (CBT) to patients 18 and older to encourage behavioral modifications that enhance diabetes management. Previously known as BT-001, AspyreRx showed statistically and clinically notable, lasting decreases in A1c when compared to standard care, alongside improvements in blood pressure, weight, mood, and overall quality of life during a randomized controlled trial.

Which Major Firms Influence Developments In The Diabetes Therapeutics Market?

Major companies operating in the diabetes therapeutics market are Pfizer Inc., Merck & Co Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Biocon Biologics Limited, MannKind Corporation, Lexicon Pharmaceuticals Inc., Adocia S.A., Oramed Pharmaceuticals Inc.

Read the full diabetes therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/diabetes-therapeutics-global-market-report

What Are The Top-Performing Regions Within The Diabetes Therapeutics Market?

North America was the largest region in the diabetes therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetes therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Diabetes Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25749&type=smp

Browse Through More Reports Similar to the Global Diabetes Therapeutics Market 2026, By The Business Research Company

Antidiabetics Market Report 2026

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Non Insulin Therapies For Diabetes Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-insulin-therapies-for-diabetes-global-market-report

Antidiabetics Market Report 2026

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Diabetes Therapeutics Market During 2026–2030?

The diabetes therapeutics market has expanded swiftly in recent years. It is anticipated to increase from $170.06 billion in 2025 to $188.19 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.7%. The expansion observed historically can be linked to the limited access to advanced therapeutic options, a reliance on conventional oral anti-diabetic drugs, inadequate awareness of preventive healthcare, restricted distribution channels, and the increasing burden of type 2 diabetes.

The diabetes therapeutics market size is projected to undergo significant expansion in the upcoming years. It is expected to reach $278.96 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.3%. This anticipated growth can be attributed to several factors including the development of novel insulin analogs, the increasing availability of combination therapies, the widespread adoption of digital diabetes management tools, enhancements in healthcare infrastructure for diabetes care, and the integration of telemedicine and remote monitoring services. Prominent trends observed during this forecast period include the rising global prevalence of diabetes, the increasing uptake of glp-1 receptor agonists and sglt-2 inhibitors, the broadening reach of online and retail pharmacies, an intensified focus on personalized diabetes management, and improved awareness regarding preventive care and early diagnosis.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25749&type=smp

Which Economic Or Industry Drivers Are Impacting The Diabetes Therapeutics Market?

The growing occurrence of obesity is projected to boost the expansion of the diabetes therapeutics market in the future. Obesity, characterized by an unhealthy excess of fat, poses a significant health hazard and stands as a primary risk factor for type 2 diabetes. The heightened incidence of obesity stems from a greater intake of high-calorie foods, as more individuals consume processed and fast foods rich in sugar and fat, coupled with reduced physical activity, resulting in substantial weight gain. Diabetes therapeutics aid in the management of obesity by enhancing blood sugar regulation and assisting with weight loss, utilizing medications like GLP-1 receptor agonists that diminish appetite and decelerate digestion, thereby improving the overall metabolic health of obese individuals. For example, a report released in May 2024 by the Office for Health Improvement and Disparities, a UK-based government department, indicated that from 2022 to 2023, roughly 64% of adults aged 18 and above were categorized as overweight or obese, representing an increase from the 63.8% recorded in the preceding year. Consequently, the rising occurrence of obesity is fueling the growth of the diabetes therapeutics market.

How Are The Various Segments Of The Diabetes Therapeutics Market Categorized?

The diabetes therapeutics market covered in this report is segmented –

1) By Drug: Oral Anti-Diabetic Drugs, Insulin, Non-Insulin Injectable Drug, Combination Drug

2) By Type: Diabetes 1, Diabetes 2

3) By Route Of Administration: Oral, Subcutaneous, Intravenous

4) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies

5) By Application: Preventive, Treatment Or Care

Subsegments:

1) By Oral Anti-Diabetic Drugs: Biguanides, Sulfonylureas, DPP-4 Inhibitors, SGLT-2 Inhibitors, Thiazolidinediones, Meglitinides, Alpha-Glucosidase Inhibitors

2) By Insulin: Rapid-Acting Insulin, Short-Acting Insulin, Intermediate-Acting Insulin, Long-Acting Insulin, Premixed Insulin

3) By Non-Insulin Injectable Drug: GLP-1 Receptor Agonists, Amylin Analogs

4) By Combination Drug: Oral Combination Therapies, Oral and Injectable Combination Therapies

What Trends Are Affecting The Expansion Of The Diabetes Therapeutics Market?

Leading companies within the diabetes therapeutics market are prioritizing the development of innovative approaches, such as cognitive behavioral therapy (CBT), to enhance customized diabetes care and improve glycemic control for individuals with type 2 diabetes. Cognitive behavioral therapy (CBT) is defined as a structured, empirically supported psychological intervention that assists people in recognizing and altering detrimental thought processes and actions. An illustrative example occurred in October 2023, when Better Therapeutics Inc., a digital therapeutics company based in the US, introduced AspyreRx, a digital application designed for diabetes therapy. AspyreRx, which secured FDA authorization for addressing type 2 diabetes, delivers personalized cognitive behavioral therapy (CBT) to patients 18 and older to encourage behavioral modifications that enhance diabetes management. Previously known as BT-001, AspyreRx showed statistically and clinically notable, lasting decreases in A1c when compared to standard care, alongside improvements in blood pressure, weight, mood, and overall quality of life during a randomized controlled trial.

Which Major Firms Influence Developments In The Diabetes Therapeutics Market?

Major companies operating in the diabetes therapeutics market are Pfizer Inc., Merck & Co Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Biocon Biologics Limited, MannKind Corporation, Lexicon Pharmaceuticals Inc., Adocia S.A., Oramed Pharmaceuticals Inc.

Read the full diabetes therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/diabetes-therapeutics-global-market-report

What Are The Top-Performing Regions Within The Diabetes Therapeutics Market?

North America was the largest region in the diabetes therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetes therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Diabetes Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25749&type=smp

Browse Through More Reports Similar to the Global Diabetes Therapeutics Market 2026, By The Business Research Company

Antidiabetics Market Report 2026

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Non Insulin Therapies For Diabetes Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-insulin-therapies-for-diabetes-global-market-report

Antidiabetics Market Report 2026

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Diabetes Therapeutics Market During 2026–2030?

The diabetes therapeutics market has expanded swiftly in recent years. It is anticipated to increase from $170.06 billion in 2025 to $188.19 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.7%. The expansion observed historically can be linked to the limited access to advanced therapeutic options, a reliance on conventional oral anti-diabetic drugs, inadequate awareness of preventive healthcare, restricted distribution channels, and the increasing burden of type 2 diabetes.

The diabetes therapeutics market size is projected to undergo significant expansion in the upcoming years. It is expected to reach $278.96 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.3%. This anticipated growth can be attributed to several factors including the development of novel insulin analogs, the increasing availability of combination therapies, the widespread adoption of digital diabetes management tools, enhancements in healthcare infrastructure for diabetes care, and the integration of telemedicine and remote monitoring services. Prominent trends observed during this forecast period include the rising global prevalence of diabetes, the increasing uptake of glp-1 receptor agonists and sglt-2 inhibitors, the broadening reach of online and retail pharmacies, an intensified focus on personalized diabetes management, and improved awareness regarding preventive care and early diagnosis.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25749&type=smp

Which Economic Or Industry Drivers Are Impacting The Diabetes Therapeutics Market?

The growing occurrence of obesity is projected to boost the expansion of the diabetes therapeutics market in the future. Obesity, characterized by an unhealthy excess of fat, poses a significant health hazard and stands as a primary risk factor for type 2 diabetes. The heightened incidence of obesity stems from a greater intake of high-calorie foods, as more individuals consume processed and fast foods rich in sugar and fat, coupled with reduced physical activity, resulting in substantial weight gain. Diabetes therapeutics aid in the management of obesity by enhancing blood sugar regulation and assisting with weight loss, utilizing medications like GLP-1 receptor agonists that diminish appetite and decelerate digestion, thereby improving the overall metabolic health of obese individuals. For example, a report released in May 2024 by the Office for Health Improvement and Disparities, a UK-based government department, indicated that from 2022 to 2023, roughly 64% of adults aged 18 and above were categorized as overweight or obese, representing an increase from the 63.8% recorded in the preceding year. Consequently, the rising occurrence of obesity is fueling the growth of the diabetes therapeutics market.

How Are The Various Segments Of The Diabetes Therapeutics Market Categorized?

The diabetes therapeutics market covered in this report is segmented –

1) By Drug: Oral Anti-Diabetic Drugs, Insulin, Non-Insulin Injectable Drug, Combination Drug

2) By Type: Diabetes 1, Diabetes 2

3) By Route Of Administration: Oral, Subcutaneous, Intravenous

4) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies

5) By Application: Preventive, Treatment Or Care

Subsegments:

1) By Oral Anti-Diabetic Drugs: Biguanides, Sulfonylureas, DPP-4 Inhibitors, SGLT-2 Inhibitors, Thiazolidinediones, Meglitinides, Alpha-Glucosidase Inhibitors

2) By Insulin: Rapid-Acting Insulin, Short-Acting Insulin, Intermediate-Acting Insulin, Long-Acting Insulin, Premixed Insulin

3) By Non-Insulin Injectable Drug: GLP-1 Receptor Agonists, Amylin Analogs

4) By Combination Drug: Oral Combination Therapies, Oral and Injectable Combination Therapies

What Trends Are Affecting The Expansion Of The Diabetes Therapeutics Market?

Leading companies within the diabetes therapeutics market are prioritizing the development of innovative approaches, such as cognitive behavioral therapy (CBT), to enhance customized diabetes care and improve glycemic control for individuals with type 2 diabetes. Cognitive behavioral therapy (CBT) is defined as a structured, empirically supported psychological intervention that assists people in recognizing and altering detrimental thought processes and actions. An illustrative example occurred in October 2023, when Better Therapeutics Inc., a digital therapeutics company based in the US, introduced AspyreRx, a digital application designed for diabetes therapy. AspyreRx, which secured FDA authorization for addressing type 2 diabetes, delivers personalized cognitive behavioral therapy (CBT) to patients 18 and older to encourage behavioral modifications that enhance diabetes management. Previously known as BT-001, AspyreRx showed statistically and clinically notable, lasting decreases in A1c when compared to standard care, alongside improvements in blood pressure, weight, mood, and overall quality of life during a randomized controlled trial.

Which Major Firms Influence Developments In The Diabetes Therapeutics Market?

Major companies operating in the diabetes therapeutics market are Pfizer Inc., Merck & Co Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Biocon Biologics Limited, MannKind Corporation, Lexicon Pharmaceuticals Inc., Adocia S.A., Oramed Pharmaceuticals Inc.

Read the full diabetes therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/diabetes-therapeutics-global-market-report

What Are The Top-Performing Regions Within The Diabetes Therapeutics Market?

North America was the largest region in the diabetes therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetes therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Diabetes Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25749&type=smp

Browse Through More Reports Similar to the Global Diabetes Therapeutics Market 2026, By The Business Research Company

Antidiabetics Market Report 2026

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Non Insulin Therapies For Diabetes Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-insulin-therapies-for-diabetes-global-market-report

Antidiabetics Market Report 2026

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the diabetes therapeutics market from 2026–2035 with trusted insights from The Business Research Company

What is the expected shift in the Diabetes Therapeutics Market’s size between 2026 and 2030?

The diabetes therapeutics market size has seen rapid expansion in recent years. It is projected to grow from $170.06 billion in 2025 to $188.19 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.7%. The growth observed in the historical period can be attributed to factors like the limited availability of advanced therapeutics, a reliance on traditional oral anti-diabetic drugs, low awareness regarding preventive care, constrained distribution channels, and the growing burden of type 2 diabetes.

The diabetes therapeutics market is projected to experience swift expansion over the coming years, with its size forecast to reach $278.96 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.3%. This anticipated growth during the forecast period is primarily driven by the development of novel insulin analogs, the proliferation of combination therapies, wider adoption of digital diabetes management tools, a strengthening healthcare infrastructure dedicated to diabetes care, and the incorporation of telemedicine and remote monitoring. Key trends anticipated for the forecast period encompass the escalating global prevalence of diabetes, the growing uptake of GLP-1 receptor agonists and SGLT-2 inhibitors, the broadening reach of online and retail pharmacies, an intensified focus on personalized diabetes management, and improved awareness regarding preventive care and early diagnosis.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25749&type=smp

Which Drivers Are Shaping Strategic Decisions In The Diabetes Therapeutics Market?

The rising incidence of obesity is anticipated to fuel the expansion of the diabetes therapeutics market. Defined as an accumulation of excessive body fat posing health risks, obesity is a significant precursor to type 2 diabetes. This growing prevalence stems from increased intake of high-calorie diets, particularly processed and fast foods rich in sugar and fat, coupled with reduced physical activity, which collectively contribute to considerable weight gain. Diabetes therapeutics aid in obesity management by enhancing blood sugar regulation and facilitating weight loss via medications like GLP-1 receptor agonists, which work by suppressing appetite and slowing digestion, thereby improving metabolic health in obese patients. An example supporting this is found in a May 2024 report by the UK’s Office for Health Improvement and Disparities, indicating that during 2022 to 2023, around 64% of adults aged 18 and above were classified as overweight or obese, representing an increase from 63.8% in the prior year. Consequently, the escalating rates of obesity are a key factor driving the growth of the diabetes therapeutics market.

What Segment Classifications Make Up The Diabetes Therapeutics Market?

The diabetes therapeutics market covered in this report is segmented –

1) By Drug: Oral Anti-Diabetic Drugs, Insulin, Non-Insulin Injectable Drug, Combination Drug

2) By Type: Diabetes 1, Diabetes 2

3) By Route Of Administration: Oral, Subcutaneous, Intravenous

4) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies

5) By Application: Preventive, Treatment Or Care

Subsegments:

1) By Oral Anti-Diabetic Drugs: Biguanides, Sulfonylureas, DPP-4 Inhibitors, SGLT-2 Inhibitors, Thiazolidinediones, Meglitinides, Alpha-Glucosidase Inhibitors

2) By Insulin: Rapid-Acting Insulin, Short-Acting Insulin, Intermediate-Acting Insulin, Long-Acting Insulin, Premixed Insulin

3) By Non-Insulin Injectable Drug: GLP-1 Receptor Agonists, Amylin Analogs

4) By Combination Drug: Oral Combination Therapies, Oral and Injectable Combination Therapies

Which Market Trends Are Opening Growth Opportunities In The Diabetes Therapeutics Market?

Leading companies in the diabetes therapeutics market are concentrating on developing innovative approaches, including cognitive behavioral therapy (CBT), to improve personalized diabetes management and enhance glycemic control for patients with type 2 diabetes. Cognitive behavioral therapy (CBT) is defined as a structured, evidence-backed psychological treatment that aids individuals in identifying and modifying unhelpful thought patterns and behaviors. For example, in October 2023, Better Therapeutics Inc., a US-based digital therapeutics company, launched AspyreRx, a digital therapeutic application for diabetes. AspyreRx, which received FDA authorization for the treatment of type 2 diabetes, offers personalized cognitive behavioral therapy (CBT) to patients aged 18 and above to support behavioral changes that contribute to better diabetes management. Formerly known as BT-001, AspyreRx demonstrated statistically and clinically significant, enduring reductions in A1c when compared to standard care, along with enhancements in blood pressure, weight, mood, and quality of life in a randomized controlled trial.

Which Major Firms Are Strengthening Their Position In The Diabetes Therapeutics Market?

Major companies operating in the diabetes therapeutics market are Pfizer Inc., Merck & Co Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Biocon Biologics Limited, MannKind Corporation, Lexicon Pharmaceuticals Inc., Adocia S.A., Oramed Pharmaceuticals Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/diabetes-therapeutics-global-market-report

Which Region Shows The Strongest Potential For Future Expansion In The Diabetes Therapeutics Market?

North America was the largest region in the diabetes therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetes therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Diabetes Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25749&type=smp

Browse Through More Reports Similar to the Global Diabetes Therapeutics Market 2026, By The Business Research Company

Antidiabetics Market Report 2026

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Non Insulin Therapies For Diabetes Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-insulin-therapies-for-diabetes-global-market-report

Antidiabetics Market Report 2026

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Big Is The Diabetes Therapeutics Market Today And What Is Its Future Size?

The market size for diabetes therapeutics has seen a swift expansion in the recent past. It is predicted to increase from $153.67 billion in 2024 to $170.06 billion in 2025, experiencing a compound annual growth rate (CAGR) of 10.7%. The escalation during the historically significant period is attributable to the initial rise in diabetes instances, increased utilization of oral hypoglycemic drugs, early adoption of injectable insulin treatments, instruction on self-care, and the arrival of biosimilar insulins on the market.

It is anticipated that the diabetes therapeutics market will experience rapid expansion in the coming years, rising to a worth of $252.95 billion in 2029, demonstrating a compound annual growth rate (CAGR) of 10.4%. The expected growth can be linked to a rise in digital literacy, increased use of injectable non-insulin medication, the development of digital health platforms, a heightened demand for personalized and combination treatments, as well as enhanced healthcare infrastructure and access to treatment for diabetes. Key trends observed during the forecast period comprise automated insulin delivery (aid) systems, the use of artificial intelligence (ai) in diabetes management, device interoperability, digital healthcare applications, and the use of remote patient monitoring (rpm).

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25749&type=smp

What External And Internal Drivers Are Influencing The Diabetes Therapeutics Market?

The escalating occurrence of obesity is projected to stimulate the expansion of the diabetes therapeutics market in the future. Obesity describes an undue accrual of fat that poses a health hazard and is a significant risk component for type 2 diabetes. The surge in obesity rates can be attributed to the mounting intake of calorie-dense diets, with an increased number of individuals consuming processed and junk foods loaded with sugar and fat, coupled with diminished physical exertion, resulting in excessive weight accumulation. Diabetes therapeutics play a crucial role in the management of obesity by enhancing blood glucose regulation and promoting weight reduction through drugs such as GLP-1 receptor agonists, which curtail appetite and decelerate digestion, thereby ameliorating the comprehensive metabolic health of obese individuals. For instance, as indicated by a report issued by the Office for Health Improvement and Disparities in the UK in May 2024, approximately 64% of adults aged 18 and above were categorized as overweight or living with obesity in 2022 to 2023, showing an escalation from the prior year’s statistic of 63.8%. Hence, the escalating prevalence of obesity is a key driver for the expansion of the diabetes therapeutics market.

How Is The Diabetes Therapeutics Market Categorized Across Applications And Types?

The diabetes therapeutics market covered in this report is segmented –

1) By Drug: Oral Anti-Diabetic Drugs, Insulin, Non-Insulin Injectable Drug, Combination Drug

2) By Type: Diabetes 1, Diabetes 2

3) By Route Of Administration: Oral, Subcutaneous, Intravenous

4) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies

5) By Application: Preventive, Treatment Or Care

Subsegments:

1) By Oral Anti-Diabetic Drugs: Biguanides, Sulfonylureas, DPP-4 Inhibitors, SGLT-2 Inhibitors, Thiazolidinediones, Meglitinides, Alpha-Glucosidase Inhibitors

2) By Insulin: Rapid-Acting Insulin, Short-Acting Insulin, Intermediate-Acting Insulin, Long-Acting Insulin, Premixed Insulin

3) By Non-Insulin Injectable Drug: GLP-1 Receptor Agonists, Amylin Analogs

4) By Combination Drug: Oral Combination Therapies, Oral and Injectable Combination Therapies

How Are Market Trends Influencing Competition In The Diabetes Therapeutics Market?

Leading corporations active in the realm of diabetes therapeutics are directing their efforts towards the creation of innovative solutions like cognitive behavioral therapy (CBT). Their intent is to amplify personalized management of diabetes and foster better glycemic control in type 2 diabetes patients. CBT is essentially a systematic, evidence-backed psychological intervention which aids individuals in identifying and transforming detrimental thought processes and behaviours. For example, in October 2023, Better Therapeutics Inc., a digital therapeutics firm from the US, unveiled AspyreRx, an innovative digital therapeutic app specifically designed for diabetes. FDA authorized, AspyreRx offers customized cognitive behavioral therapy (CBT) for patients 18 years or older in order to bolster behavioral alterations which amplify diabetes management. Initially labeled as BT-001, AspyreRx has proven to induce significant and enduring reductions in A1c when compared to conventional care. These results were consistent with a decided enhancement in factors such as blood pressure, body weight, emotional health and overall quality of life, as reflected in a randomized controlled trial.

Who Are The Global Leaders Steering The Diabetes Therapeutics Market Forward?

Major companies operating in the diabetes therapeutics market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, Medtronic plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Biocon Biologics Limited, MannKind Corporation, Tandem Diabetes Care Inc., Lexicon Pharmaceuticals Inc., Better Therapeutics Inc., Adocia S.A., Oramed Pharmaceuticals Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/diabetes-therapeutics-global-market-report

What Are The Emerging Regional Trends Driving The Diabetes Therapeutics Market?

North America was the largest region in the diabetes therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetes therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=25749&type=smp

Browse Through More Reports Similar to the Global Diabetes Therapeutics Market 2025, By The Business Research Company

Clinical Nutrition For Diabetes Care Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/clinical-nutrition-for-diabetes-care-global-market-report

Antidiabetics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Diabetes Care Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/diabetes-care-devices-market

About The Business Research Company:

With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Much Is the Global Diabetes Therapeutics Market Valued at Present and by 2029?

The market size for diabetes therapeutics has seen a swift expansion in recent years. The growth is projected to surge from $153.67 billion in 2024 to $170.06 billion in 2025, representing a Compound Annual Growth Rate (CAGR) of 10.7%. Several factors are contributing to this increase during the historic period, such as the initial rise in diabetes occurrence, extensive deployment of oral hypoglycemic medications, early incorporation of injectable insulin treatments, self-management awareness initiatives, and the introduction of biosimilar insulins to the market.

The market size for diabetes therapeutics is anticipated to experience expeditious expansion in the forthcoming years, reaching $252.95 billion by 2029 with a 10.4% compound annual growth rate (CAGR). Factors influencing this significant growth over the projected period include escalating digital literacy, greater acceptance of injectable non-insulin medicines, expansion of digital healthcare platforms, a surge in demand for personalized and combination treatments, as well as the enhancement of healthcare infrastructure and access to diabetes care. Key trends to observe during the forecast period involve automated insulin delivery (AID) systems, the application of artificial intelligence (AI) in diabetes management, device interoperability, utilisation of digital health applications, and the remote monitoring of patients.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25749&type=smp

#What Drivers Are Influencing Growth In The Diabetes Therapeutics Market?

The escalating rates of obesity are anticipated to fuel the expansion of the diabetes therapeutics market. Defined as an unhealthy accumulation of excessive fat, obesity is a significant risk element for type 2 diabetes. The upsurge in obesity rates is attributed to the growing consumption of high-calorie diets, with a larger portion of the populace eating sugar and fat-rich fast and processed foods. At the same time, physical activity levels are lowering, causing excessive weight gain. Diabetes therapeutics are beneficial in managing obesity as they enhance blood sugar control and assist in weight loss. They employ medications such as GLP-1 receptor agonists that diminish appetite and decelerate digestion, thus augmenting metabolic health in obese individuals. For example, a report released by the Office for Health Improvement and Disparities, a UK government department, in May 2024 indicated that roughly 64% of adults aged 18 and over were categorised as overweight or suffering from obesity in 2022 to 2023. This depicts an increase from the previous year’s statistic of 63.8%. As a result, the escalating rates of obesity are propelling the expansion of the diabetes therapeutics market.

What Are The Main Segments Identified In The Diabetes Therapeutics Market Research?

The diabetes therapeutics market covered in this report is segmented –

1) By Drug: Oral Anti-Diabetic Drugs, Insulin, Non-Insulin Injectable Drug, Combination Drug

2) By Type: Diabetes 1, Diabetes 2

3) By Route Of Administration: Oral, Subcutaneous, Intravenous

4) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies

5) By Application: Preventive, Treatment Or Care

Subsegments:

1) By Oral Anti-Diabetic Drugs: Biguanides, Sulfonylureas, DPP-4 Inhibitors, SGLT-2 Inhibitors, Thiazolidinediones, Meglitinides, Alpha-Glucosidase Inhibitors

2) By Insulin: Rapid-Acting Insulin, Short-Acting Insulin, Intermediate-Acting Insulin, Long-Acting Insulin, Premixed Insulin

3) By Non-Insulin Injectable Drug: GLP-1 Receptor Agonists, Amylin Analogs

4) By Combination Drug: Oral Combination Therapies, Oral and Injectable Combination Therapies

What Are The Leading Trends And Opportunities In The Diabetes Therapeutics Sector?

Leading corporations in the diabetes therapeutics market are placing emphasis on creating cutting-edge solutions like cognitive behavioral therapy (CBT) to augment personalized diabetes care and better manage blood sugar levels in type 2 diabetes patients. CBT is a structured, scientifically supported psychological treatment that enables individuals to recognize and adjust dysfunctional thought patterns and behaviors. In October 2023, the US-based digital therapeutics firm, Better Therapeutics Inc., introduced AspyreRx, a digital therapeutic app for diabetes. The FDA-authorized AspyreRx offers customized cognitive behavioral therapy (CBT) to individuals 18 years and older, encouraging behavioral modifications for better diabetes control. Originally known as BT-001, the clinical and statistical significance of AspyreRx in reducing A1c levels compared to standard treatment was demonstrated, along with enhanced blood pressure, weight, mood, and quality of life indicators in a randomized controlled trial.

Which Companies Play A Key Role In The Development Of The Diabetes Therapeutics Market?

Major companies operating in the diabetes therapeutics market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, Medtronic plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Biocon Biologics Limited, MannKind Corporation, Tandem Diabetes Care Inc., Lexicon Pharmaceuticals Inc., Better Therapeutics Inc., Adocia S.A., Oramed Pharmaceuticals Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/diabetes-therapeutics-global-market-report

What Are The Key Regional Developments Shaping The Diabetes Therapeutics Market?

North America was the largest region in the diabetes therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetes therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=25749&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model